

- National Cancer Institute. Endometrial cancer prevention (PDQ). <http://www.cancer.gov/cancertopics/pdq/prevention/endometrial/>. Accessed September 3, 2014.
- National Cancer Institute. SEER stat fact sheets: Corpus and uterus, NOS. <http://seer.cancer.gov/statfacts/html/corp.html#risk>. Accessed April 16, 2012.
- National Cancer Institute. Uterine sarcoma. <http://www.cancer.gov/cancertopics/types/uterinesarcoma>. Accessed April 16, 2012.
- Broadus R. Pathology of Lynch syndrome-associated gynecological cancers. In: Lu KH, ed. *Hereditary Gynecologic Cancer: Risk, Prevention, and Management*. New York: Informa Healthcare; 2008:149–162.
- Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: A review of selected histological subtypes. *Cancer Control* 2009;16:46–52.
- Buchanan EM, Weinstein LC, Hillson C. Endometrial cancer. *Am Fam Physician* 2009;80:1075–1080.
- Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. *Am J Obstet Gynecol* 2003;188:100–107.
- Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res* 2006;66:7810–7817.
- Hampel H, Panescu J, Lockman J, et al. Comment on: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res* 2007;67:9603.
- Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology* 2009;137:1621–1627.
- Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. *Gastroenterology* 2005;129:415–421.
- Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. *J Clin Oncol* 2007;25:5158–5164.
- Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. *J Clin Oncol* 2003;21:4364–4370.
- Millar AL, Pal T, Madlensky L, et al. Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. *Hum Mol Genet* 1999;8:823–829.
- Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. *J Clin Oncol* 2008;26:5965–5971.
- Balmana J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. *JAMA* 2006;296:1469–1478.
- Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA* 2006;296:1479–1487.
- Backes FJ, Leon ME, Ivanov I, et al. Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. *Gynecol Oncol* 2009;114:486–490.
- Kwon JS, Scott JL, Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome. *J Clin Oncol* 2011;29:2247–2252.
- Weissman SM, Belleross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome—a review. *J Genet Couns* 2011;20:5–19.
- National Comprehensive Cancer Network. Colorectal cancer screening, V1. 2012. [http://www.nccn.org/professionals/physician\\_gls/pdf/colorectal\\_screening.pdf](http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf). Accessed April 16, 2012.
- Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. *Oncogene* 1998;17:2413–2417.
- Kawaguchi M, Yanokura M, Banno K, et al. Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. *Int J Oncol* 2009;34:1541–1547.
- Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304–2310.
- Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. *Gastroenterology* 2008;135:419–428.
- Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: A cohort study. *Lancet Oncol* 2011;12:49–55.
- Lynch HT, Riegert-Johnson DL, Snyder C, et al. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. *Am J Gastroenterol* 2011;106:1829–1836.
- Broadus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma. *Cancer* 2006;106:87–94.
- Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med* 2006;354:261–269.
- Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. *JAMA* 2006;296:1507–1517.
- Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). *J Med Genet* 2007;44:353–362.
- Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol* 2003;91:74–80.
- Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer* 2002;94:1708–1712.
- Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. *J Int Cancer* 2007;120:821–824.
- Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J Med Genet* 2005;42:318–321.
- Varga EA, Pastore M, Prior T, et al. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. *Genet Med* 2009;11:111–117.
- Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400–407.
- Pilarski R. Cowden syndrome: A critical review of the clinical literature. *J Genet Couns* 2009;18:13–27.
- Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. *Am J Hum Genet* 2011;88:42–56.
- Eng C. PTEN hamartoma tumor syndrome (PHTS). In: Pagon RA, Bird TD, Dolan CR, et al., eds. *Gene Reviews*. Seattle, WA: University of Washington, Seattle; 1993.
- Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: An evaluation of Cowden syndrome and Bannayan-Riley-Rivulacaba syndrome clinical features. *J Med Genet* 2011;48:505–512.
- Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. *Clin Genet* 1986;29:222–233.
- Schmeler KM, Daniels MS, Brandt AC, et al. Endometrial cancer in an adolescent: A possible manifestation of Cowden syndrome. *Obstet Gynecol* 2009;114:477–479.
- Black D, Bogomolny F, Robson ME, et al. Evaluation of germline PTEN mutations in endometrial cancer patients. *Gynecol Oncol* 2005;96:21–24.
- National Comprehensive Cancer Network. Genetic/clinical high-risk assessment: breast and ovarian, V1.2011. [www.nccn.org](http://www.nccn.org). Accessed April 7, 2011.
- Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: An online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. *BMC Med Genet* 2008;9:20.
- Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. *Am J Hum Genet* 2003;73:95–106.
- Stewart L, Glenn GM, Stratton P, et al. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. *Arch Dermatol* 2008;144:1584–1592.
- Alam NA, Barclay E, Rowan AJ, et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: An underdiagnosed tumor syndrome. *Arch Dermatol* 2005;141:199–206.
- Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: Update on clinical and molecular characteristics. *Fam Cancer* 2011;10:397–411.
- Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, et al. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. *Int J Cancer* 2006;119:283–287.
- Gardie B, Remenieras A, Kattygnarath D, et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. *J Med Genet* 2011;48:226–234.
- Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet* 2006;43:18–27.
- Alarshdi I, Levine S, Paterson J, et al. Hereditary leiomyomatosis and renal cell carcinoma: Very early diagnosis of renal cancer in a paediatric patient. *Fam Cancer* 2010;9:239–243.
- Lavie O, Homreich G, Ben-Arie A, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. *Gynecol Oncol* 2004;92:521–524.
- Barak F, Milgram R, Laitman Y, et al. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. *Gynecol Oncol* 2010;119:511–515.
- Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. *Gynecol Oncol* 2001;80:395–398.
- Francis JH, Kleiner RA, Seddon JM, et al. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. *Gynecol Oncol* 2012;124:254–259.